Killing rates (K) of 1-32 mg ml "1 caspofungin were determined in RPMI-1640 and in 50 % serum using time-kill methodology against three Candida krusei (MICs of all three isolates 0.25 mg ml
INTRODUCTION
The echinocandins are the newest antifungal class introduced into clinical practice, and have good efficacy and an excellent safety profile (Andes et al., 2010; Cornely et al., 2011; Mukherjee et al., 2011; Pappas et al., 2009) . These drugs are active against triazole-resistant Candida species (e.g. Candida krusei, Candida inconspicua). Because of the recognized increase in fluconazole-resistant Candida infections, echinocandins are currently the first choice for the treatment of invasive Candida infections, including empirical therapy of candidaemias (Pappas et al., 2009; Pfaller & Diekema, 2007; Pfaller et al., 2011) .
C. krusei is an important bloodstream pathogen that is responsible for up to 5 % of invasive Candida infections (Pfaller & Diekema, 2007; Pfaller et al., 2012; Tortorano et al., 2012) . This species is common among neutropenic patients and patients receiving antifungal prophylaxis or corticosteroid therapy. Because C. krusei is resistant to fluconazole, echinocandins are the preferred therapy according to guidelines from the Infectious Diseases Society of America (Chen et al., 2011; Pappas et al., 2009) . According to the Prospective Antifungal Therapy Alliance registry, 113 out of 3648 patients suffered from C. krusei candidaemia between 2004 and 2008. C. krusei candidaemia showed the lowest 90-day survival rate (53.6 %) among the five most important Candida species. Importantly, 92 % of these patients received echinocandin therapy, suggesting that the activity of echinocandins may be suboptimal against this species (Pfaller et al., 2012) . Moreover, data on the efficacy of echinocandins against less common species are mostly anecdotal (Pfaller et al., 2011) . Therefore, the aim of our study was to determine the in vitro and in vivo activity of caspofungin (CAS) against C. krusei clinical isolates in order to gain a better understanding of the activity of this drug. Because CAS is a highly proteinbound drug (Andes et al., 2010; Chen et al., 2011; Pfaller et al., 2011) , CAS killing activity was determined in both RPMI-1640 and 50 % serum. A less common fluconazoleresistant Candida species, C. inconspicua, was also investigated (Majoros et al., 2003; Pfaller & Diekema, 2007) .
This work was presented at 6th Trends in Medical Mycology meeting, 11-14 October 2013, Copenhagen, Denmark, poster number: P011.
METHODS
Isolates. All three C. krusei isolates (isolate numbers 4363, 5029 and 27393) and one (isolate number 20114) of three C. inconspicua isolates were isolated from blood samples. The remaining two C. inconspicua isolates were isolated from peritoneal (isolate number 22027) and wound samples (isolate number 12060). C. krusei type strain ATCC 6258 and one echinocandin-resistant C. krusei isolate (DPL45, FKS F645F/C; courtesy of Professor D. S. Perlin) were also included in the study. C. krusei clinical isolates were identified by APID32C and Matrix-assisted laser desorption/ionization time of flight, while C. inconspicua isolates were identified using molecular biological methods (Majoros et al., 2003) .
Determination of the in vitro activity of CAS. CAS MICs were determined using the CLSI standard broth macrodilution method (M27-A3) in RPMI-1640, with and without 50 % human serum (from a human male, blood type AB; Sigma), at least twice (CLSI, 2008; Földi et al., 2012a; Garcia-Effron et al., 2011) . CAS final concentrations ranged between 0.015 and 32 mg ml 21 . MICs were read after 24 h using the partial inhibition criterion (at least 50 % growth reduction as compared with the growth control) (CLSI, 2008) .
In killing studies, CAS activity was measured in RPMI-1640 with and without 50 % human serum at 0.5-166 MIC in a final volume of 10 ml using a starting inoculum of approximately 10 5 cells ml 21 (Földi et al., 2012a, b; Szilágyi et al., 2012a) . However, the highest CAS concentration used during in vitro studies was 32 mg ml
21
(regardless of MIC), because the current maximum administrable daily doses of CAS (150-200 mg) produce 30.4-40.6 mg ml 21 geometric mean of peak concentrations in humans (Cornely et al., 2011) . For comparison of killing with and without serum, we used the concentration range 1-32 mg ml 21 .
The initial inoculum size was determined as described below. Samples (100 ml) were removed at 0, 4, 8, 12, 24 and 48 h, serially diluted 10-fold, plated (4630 ml) onto a single Sabouraud dextrose agar (SDA) and incubated at 35 uC for 48 h (Cantó n et al., 2009 (Cantó n et al., , 2010 Földi et al., 2012a, b; Szilágyi et al., 2012a) . All experiments were performed in both media at least twice. Time-kill curves were prepared using the computer curve-fitting software GraphPad Prism 4.03 for Windows.
Analysis of in vitro data. Fungicidal or fungistatic activity of CAS was defined as a reduction of 99.9 % or higher in viable cell count compared with the starting inoculum, respectively (Cantó n et al., 2009 (Cantó n et al., , 2010 Földi et al., 2012a, b; Szilágyi et al., 2012a) .
The killing kinetics of the fungicidal activity of CAS at ¢1 mg ml 21 in both media (RPMI-1640 and 50 % serum) were analysed by fitting the mean data at each time point to an exponential equation:
, where N t is the number of viable yeasts at time t, N 0 is the number of viable yeasts at the beginning of the experiment, K is the killing rate, and t is the incubation time. Thus, the six time points on each killing curve were reduced to one value (K) (Cantó n et al., 2009 (Cantó n et al., , 2010 .
The goodness of fit for each isolate was assessed using the r 2 value (.0.8). Positive K values indicate growth and negative K values indicate killing. The times (h) to achieve 50, 90, 99 and 99.9 % reductions in c.f.u. compared with the starting inoculum size were calculated from the K value (T 50 50.30103/K, T 90 51/K, T 99 52/K, T 99.9 53/K) for each CAS concentration and each strain (Cantó n et al., 2009 (Cantó n et al., , 2010 .
One-way ANOVA with Tukey's post-testing was used to determine significant differences in killing kinetics among isolates and concentrations in either RPMI-1640 or 50 % serum. A t-test (with Welch's correction, where appropriate) was used for the same CAS concentrations in RPMI-1640 and 50 % serum to determine significant differences in killing kinetics between the different media.
In vivo studies. Groups of seven to nine female BALB/c mice (21-23 g) were given cyclophosphamide 4 days before infection (150 mg kg 21 ), 1 day before infection (100 mg kg 21 ) and 2 and 5 days postinfection (each 100 mg kg 21 ) (Andes et al., 2010; Földi et al., 2012b) . The animals were maintained in accordance with Guidelines for the Care and Use of Laboratory Animals; experiments were approved by the Animal Care Committee of the University of Debrecen (permission no. 12/2008). In vivo experiments were performed using two clinical isolates of each species (C. krusei isolates 5029 and 27393, C. inconspicua isolates 20114 and 22027) as well as the echinocandinresistant C. krusei isolate DPL45. Mice were infected intravenously through the lateral tail vein; based on our preliminary experiments, the infectious doses of C. krusei and C. inconspicua were 4610 6 and 2610 7 c.f.u. per mouse, respectively. Inoculum density was confirmed by plating serial dilutions onto SDA plates.
Five days of intraperitoneal treatment with daily 1, 2, 3, 5 and 15 mg kg 21 CAS (Cancidas, commercial preparation) was started after 24 h post-infection (Szilágyi et al., 2012b) . All mice were killed on day 6 post-infection, and both kidneys of each mouse were removed, weighed and homogenized aseptically. Aliquots of 0.1 ml of the undiluted and diluted (1 : 10) homogenates were plated onto SDA plates and incubated at 35 uC. Values for c.f.u. were determined after 48 h. The lower limit of detection was 50 c.f.u. g 21 tissue. Kidney burden was analysed using a Kruskal-Wallis test with Dunn's posttest for multiple comparisons.
RESULTS

In vitro experiments
CAS MICs and killing study results in RPMI-1640 and 50 % serum are shown in Table 1 . C. krusei clinical isolates were susceptible to CAS according to the revised CLSI breakpoints in RPMI-1640. The C. krusei isolate DPL45 was resistant to CAS (Pfaller et al., 2011) . MIC values were increased four-to eightfold in 50 % serum for both C. krusei and C. inconspicua (Table 1) .
Mean time-kill data of the three clinical isolates of both Candida species are shown in Fig. 1 . Table 2 shows the mean time needed to kill 50, 90, 99 and 99.9 % of the starting inoculum of the two species by each CAS concentration in both media, as obtained from the K value of each killing curve regression line (Cantó n et al., 2009 (Cantó n et al., , 2010 . (Table 2 ). Strain C. krusei ATCC 6258 was killed by ¢1 mg ml 21 CAS (¢46 MIC) after 12-24 h. CAS was fungistatic against the resistant strain (C. krusei DPL45) at ¢4 mg ml 21 in the first 12 h, but regrowth was noticed after 24-48 h. However, 32 mg ml 21 CAS (46 MIC) proved to be fungicidal (Table 2) .
Serum markedly decreased the activity of CAS against C. krusei. In 50 % serum at 1 mg ml 21 (0.56 MIC), all three C. krusei isolates were inhibited by CAS in the first 4 h, but after 12-24 h killing curves became similar to the control curves (Fig. 1b) . CAS at 2-4 mg ml 21 (1-26 MIC) was fungistatic against C. krusei isolates, but regrowth was observed after 24 h. C. krusei clinical isolates reached the fungicidal endpoint after 6.47±3.48 and 7.42±5.91 h at 16 and 32 mg ml 21 CAS, respectively (Table 2) . Similar killing was noticed in the case of the ATCC 6258 strain. CAS showed a fungistatic effect against C. krusei strain DPL45, reaching the maximum c.f.u. decreases at 16-32 mg ml 21 (-lg1.82-lg2.44) after 12 h, but regrowth occurred after 24-48 h and the curves became similar to the control as opposed to the data with RPMI-1640 without serum.
CAS at 16 MICs (0.06-0.12 mg l
21
) was fungistatic against C. inconspicua in RPMI-1640; all three isolates were killed at ¢0.5 mg ml 21 CAS (4-86 MIC) at 24 h (Fig. 1c) . In 50 % serum, all three C. inconspicua isolates were inhibited at 16 MIC (0.25-0.5 mg ml
) in the first 24 h, but regrowth was observed after 48 h. The fungicidal endpoint was reached significantly faster at 1-32 mg ml 21 CAS in 50 % serum than in RPMI-1640 (Table 2 , Fig. 1d) The relationship between the killing rate and CAS concentrations was linear in both media for both Candida species (Fig. 2) . In case of C. krusei clinical isolates, the highest killing rate was noticed at 4 mg CAS ml 21 in RPMI-1640, which was significantly higher than at 2 and 32 mg ml 21 (P,0.05). In 50 % serum, the mean K values (range 20.42 to 20.57 h 21 ) at effective CAS concentrations (4-32 mg ml 21 ) did not differ significantly (P.0.05) (Fig. 2) . The killing rates at 1, 2 and 4 mg CAS ml 21 were significantly higher in RPMI-1640 than in 50 % serum (P,0.01-0.005).
In the case of C. krusei ATCC 6258, at 1 mg ml 21 (0.56 MIC) growth occurred in 50 % serum, as opposed to RPMI-1640 without serum (Fig. 2) . At 2-32 mg CAS ml 21 (1-326 MIC) the K value in RPMI-1640 and 50 % serum ranged from 20.46 to 20.96 and from 20.87 to 21.37 h
, respectively. The killing rates at 8 and 16 mg ml 21 CAS were significantly higher in 50 % serum than in RPMI-1640 (P,0.01).
In the case of the CAS-resistant DPL45 strain, with the exception of 32 mg ml 21 CAS in RPMI-1640 (the K value at 32 mg ml 21 was 21.12 1 h 21 ), killing was observed in neither RPMI-1640 nor 50 % serum (Fig. 2) .
Adding 50 % serum significantly increased the CAS killing activity against C. inconspicua at all concentrations tested between 1 and 32 mg ml 21 (range 21.12 to 21.44 h 21 ; P,0.0003 for all tested concentrations; Fig. 2 ). Different CAS concentrations did produce significantly different K values within the same medium (RPMI-1640 or 50 % serum).
In vivo experiments
All CAS doses decreased the fungal tissue burden by the two C. krusei clinical isolates, but only the 3, 5 and 15 mg kg 21 daily doses were effective (P,0.05-0.001; Fig. 3a, b ). All effective doses were comparable in efficiency for both isolates (P.0.05). Only the highest CAS dose (15 mg kg 21 ) was effective against the C. krusei strain DPL45 (P,0.01; Fig. 3c ).
In the case of C. inconspicua, all treatment arms decreased the fungal tissue burden in the kidneys at least with two log degrees, which corresponded to a significantly (P,0.05-0.001) lower tissue burden than seen in the untreated control (Fig. 3d, e) . Moreover, in the case of C. inconspicua isolate 20114, the fungal tissue burden decreases were higher than four log decreases in mice treated with 5 and 15 mg kg 21 daily doses (Fig. 3e) . However, significant differences were not noticed among the effective doses (P.0.05).
DISCUSSION
Echinocandins show concentration-dependent pharmacodynamic activity against susceptible fungi; thus, dose escalation seems to be an option for improving clinical efficacy (Andes et al., 2010; Chen et al., 2011; Mukherjee et al., 2011) . In humans, the maximum tolerated daily doses for micafungin and CAS are 900 and 210 mg, respectively (Cornely et al., 2011; Sirohi et al., 2006) . However, the benefit of higher dosing of echinocandins for the treatment of invasive Candida infections is still controversial (Betts et al., 2009; Pappas et al., 2007) .
The clinical efficacy of dose escalation may be fundamentally influenced by the high degree of protein binding (¢97 %) of echinocandin antifungals (Andes et al., 2010; Chen et al., 2011; Mukherjee et al., 2011) . This is modelled in vitro by adding serum to the test medium; many studies have been performed to compare the activity of echinocandins against Candida and Aspergillus species with and without serum. Both MIC determinations and killing studies have revealed that serum negatively modulates the activity of echinocandins (i.e. MIC values were increased or higher echinocandin concentrations were needed to reach the fungicidal effect) (Földi et al., 2012a, b; Garcia-Effron et al., 2011; Ishikawa et al., 2009; Odabasi et al., 2007; Paderu et al., 2007; Spreghini et al., 2012; Szilágyi et al., 2012a) . However, two studies have reported that serum can enhance the activity of CAS against Candida glabrata and Aspergillus fumigatus (Chiller et al., 2000; Wiederhold et al., 2007) . Moreover, serum-based MIC determination has been reported to identify clinical isolates with acquired mechanisms of resistance against echinocandins more efficiently than the standard method (Garcia-Effron et al., 2011). Unfortunately, serum-based susceptibility methods have not yet been standardized (Nasar et al., 2013 
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21
) using RPMI-1640 as test medium. The mean time to reach the fungicidal endpoint at 8 and 32 mg ml 21 was 29.2±6.0 and 21.4±5.9 h, respectively, as calculated from the killing rate (K) (Cantó n et al., 2009) . The corresponding data in our study were different (4.2± .48 h at 8 mg ml 21 CAS and 4.64±0.33 h at 32 mg ml 21 CAS); however, CAS MIC values against C. krusei were lower (0.25 mg ml 21 for all three isolates) in our study. This discrepancy confirms that even slightly higher MIC values may lead to a marked decrease in or loss of killing activity, which is reflected in the newer breakpoints (the breakpoint of ¡2 mg ml 21 was changed to ¡0.25 mg ml 21 ) (Pfaller et al., 2011) . These data also show that killing kinetics can differ even among isolates with similar or identical MICs.
Adding 50 % serum to the medium increased MIC values four-to eightfold against both species. The killing rate at effective CAS concentrations (4-32 mg ml 21 ) was concentration independent against C. krusei clinical isolates, since no statistically significant differences were noted among the different CAS concentrations tested. This means that when a critical effective concentration is achieved, further concentration increases hardly influence the results.
Although the reference strain behaved slightly differently, this can be attributed to long in vitro storage or strain variation (the reference strain was isolated from sputum as opposed to the clinical isolates, which originated from blood).
These results were also confirmed in the neutropenic murine model. Both in vitro and in vivo results suggest that a very high dose of CAS (and probably of other echinocandins as well) does not offer much therapeutic benefit against C. krusei. However, dose escalation of CAS to 15 mg kg 21 day -1 proved to be effective against the heterozygous C. krusei mutant strain in vivo. Similar results were obtained by Wiederhold et al. (2011) , who found 10 mg kg 21 CAS to be efficacious against one of two echinocandin-resistant C. albicans isolates in reducing the fungal tissue burden. However, these results remain anecdotal and their clinical utility is unknown.
Interestingly, C. inconspicua behaved differently. Although the MICs were increased slightly by 50 % serum, CAS at 1-32 mg ml 21 concentrations significantly increased killing rates in 50 % serum against C. inconspicua when compared with RPMI-1640. Similar results have been reported for C. glabrata and A. fumigatus by Chiller et al. (2000) and Wiederhold et al. (2007) ; however, Chiller et al. (2000) used only 5 % serum in their experiments. The killing activity of CAS against C. inconspicua, similarly to C. krusei, was concentration independent, but started at concentrations as low as 1 mg ml 21 CAS. In the neutropenic mouse model, 1 mg kg 21 CAS day -1 proved to be effective, significantly decreasing the fungal burden in the kidneys and suggesting that CAS is a highly effective therapy against this rare fluconazole-resistant opportunistic yeast. This is the first study in which the killing rate produced by an echinocandin drug has been compared head to head in RPMI-1640 and 50 % serum against Candida species. CAS MICs were increased by 50 % serum, and there were no differences between concentrations with significant efficacy as opposed to RPMI-1640 without serum. The killing activity of CAS against C. inconspicua, but not against C. krusei, was significantly higher in the presence of 50 % serum. For these reasons, the clinical utility of echinocandin dose escalation against the two species tested is questionable. Further preclinical and clinical studies are needed to confirm that dose escalation offers any benefit against Candida species when compared with the presently used standard echinocandin therapeutic strategy.
